Micafungina Accord (Micafungin)

Micafungin inhibits the fungal enzyme 1,3‑β‑D‑glucan synthase, which is essential for synthesizing β‑glucan, a key structural component of the fungal cell wall. This disruption weakens the cell wall, leading to osmotic instability and fungal cell death.

The appropriate dose of Micafungina Accord is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. Dosage regimens are not standardized in public literature.

Micafungina Accord is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus, but adequate human data are lacking. It should be used during pregnancy only if clearly needed, and breastfeeding decisions should consider the potential for drug excretion in milk.

To order Micafungina Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Micafungina Accord belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins generally have a favorable safety profile, limited drug‑drug interactions, and are fungicidal against most Candida species, making them a preferred option for serious invasive infections.

Micafungina Accord should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Micafungina Accord is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional under aseptic conditions, typically infused over a period of 30‑60 minutes, depending on the prescribed regimen and patient tolerance.

Serious risks include severe hepatic dysfunction, anaphylactic or severe hypersensitivity reactions, acute renal failure, and rare dermatologic events such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of liver injury, allergic reactions, and renal impairment during therapy.

Micafungina Accord should be avoided in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic or renal impairment, and it should be used only when the benefits outweigh potential risks in pregnant or breastfeeding women.